NEO News Alert Neogenomics Inc (NEO) 4.13 12/17/2014 03:31:2

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Neogenomics Inc (NEO) 4.13 $NEO

NeoGenomics, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and the Northwestern Medicine Developmental Therapeutics Institute Launch Collaborative Translational Research Program
PR Newswire - Tue Dec 16, 6:00AM CST
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has entered into a research agreement with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Lurie Cancer Center) and the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) that will provide the basis to initiate a broad-spectrum translational program designed to expand the established clinical utility of comprehensive genomic profiling technologies in the development of oncology therapeutics from early pre-clinical studies to clinical practice.
NEO: 4.13 (+0.04)

United States Medical Laboratories Industry Analytics 2014-2021 - Extensive Financial Benchmarks, Metrics and Revenue Forecasts
M2 - Mon Dec 15, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/lncwzs/medical) has announced the addition of Plunkett Research Ltd's new report "Medical Laboratories Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Key Findings: - Medical Laboratories Industry (U.S.) to reach $218.2 billion by 2021. - Medical Laboratories Industry, including Average EBITDA, Operating Ratios and Sales per Employee. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies - AmeriPath Inc - Bio-Reference Laboratories Inc - Genomic Health Inc - Hooper Holmes Inc - Laboratory Corp of America Holdings - MEDTOX Scientific Inc - Medytox Solutions Inc - NeoGenomics Inc - Psychemedics Corporation - Quest Diagnostics Inc For more information visit http://www.researchandmarkets.com/research/lncwzs/medical Source: Plunkett Research Ltd
PMD: 14.36 (+0.65), HH: 0.50 (-0.01), BRLI: 28.44 (+0.61), NEO: 4.13 (+0.04), DGX: 62.92 (-0.29), LH: 101.90 (+0.54), GHDX: 30.54 (+0.01)

United States Medical and Diagnostic Laboratories Industry Analytics 2014-2021 - Extensive Financial Benchmarks, Metrics and Revenue Forecasts
M2 - Mon Dec 15, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/k6lcqc/medical_and) has announced the addition of Plunkett Research Ltd's new report "Medical and Diagnostic Laboratories Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Key Findings: - Medical and Diagnostic Laboratories Industry (U.S.) to reach $80.8 billion by 2021. - Medical and Diagnostic Laboratories Industry, including Average EBITDA, Operating Ratios and Sales per Employee. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital Comparison of Individual Top Publicly-Held Companies to Industry Averages, 2013 - Income Statements. Balance Sheets and Cash Flow Statements Companies Mentioned - Alliance Healthcare Services Inc - AmeriPath Inc - Bio-Reference Laboratories Inc - Genomic Health Inc - Hooper Holmes Inc - Laboratory Corp of America Holdings - MEDTOX Scientific Inc - NeoGenomics Inc - Quest Diagnostics Inc - RadNet Inc For more information visit http://www.researchandmarkets.com/research/k6...edical_and Source: Plunkett Research Ltd
HH: 0.50 (-0.01), BRLI: 28.44 (+0.61), RDNT: 8.59 (+0.17), NEO: 4.13 (+0.04), DGX: 62.92 (-0.29), LH: 101.90 (+0.54), GHDX: 30.54 (+0.01)

N-of-One Selected by NeoGenomics to Provide Clinical Evidence for Interpreting Solid Tumor Next-Generation Sequencing Tests
Business Wire - Tue Dec 02, 7:31AM CST
N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, today announced an agreement with NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services. Under this agreement, N-of-One will provide clinical and interpretive evidence for NeoGenomics solid tumor next-generation sequencing (NGS) tests being used by community pathologists and oncologists. Financial terms of the agreement are not disclosed.
NEO: 4.13 (+0.04)

Midday Gainers/ Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 11:49AM CST

FRM: 7.08 (-0.31), NEO: 4.13 (+0.04), AU: 7.52 (+0.04), FNHC: 24.46 (unch), AMS: 2.37 (-0.10), NYMX: 0.41 (+0.01), AMDA: 0.64 (-0.02), CVD: 102.05 (+0.43), GBIM: 6.85 (unch), RCAP: 10.90 (+0.44), KBIO: 1.66 (-0.05), COOL: 0.59 (-0.04), SAPE: 24.79 (-0.04), XTLB: 2.51 (+0.01), GERN: 3.04 (+0.06), ANIP: 55.08 (+1.32), BBLU: 1.10 (+0.23), NXTD: 2.34 (-0.05), AP: 17.49 (-0.13), ALQA: 3.94 (-0.04)

NeoGenomics' (NEO) CEO Doug VanOort on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 02, 1:31AM CDT

NEO: 4.13 (+0.04)

Neogenomics raises full year 2014 guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 8:51AM CDT

NEO: 4.13 (+0.04)

Neogenomics beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 6:26AM CDT

NEO: 4.13 (+0.04)

NeoGenomics Reports 38% increase in Revenue to a Record $23.2 Million and Adjusted EBITDA of $2.6 Million for the Third Quarter of 2014
PR Newswire - Thu Oct 30, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the third quarter of 2014.
NEO: 4.13 (+0.04)

NeoGenomics to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, October 30, 2014
ACCESSWIRE - Wed Oct 29, 3:13PM CDT
FT. MYERS, FL / ACCESSWIRE / October 29, 2014 / NeoGenomics Inc. (NASDAQ:NEO) will host a conference call and live webcast to discuss the results of the third quarter 2014, to be held Thursday, October 30, 2014 at 11:00 AM Eastern Time.
NEO: 4.13 (+0.04)

NeoGenomics is First to Offer Molecular Testing for Resistance to Bruton Tyrosin Kinase Inhibitors for Chronic Lymphocytic Leukemia
PR Newswire - Thu Oct 23, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has launched new tests for the detection of mutations in the Bruton tyrosine kinase (BTK) and PLC-gama2 genes for predicting acquired resistance to BTK inhibitors. In addition, NeoGenomics launched a lymphoma profiling test specifically to predict susceptibility to BTK inhibitors and test for mutations in CXCR4, CD79B, MYD88, and CARD11 genes in various types of lymphoma.
NEO: 4.13 (+0.04)

NeoGenomics Launches 315 Gene Next Generation Sequencing Test for Solid Tumor Discovery Profiling
PR Newswire - Thu Oct 16, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today the addition of a new comprehensive solid tumor profiling test designed for clinical discovery and to support clinical trials. The test utilizes next generation sequencing ("NGS" to analyze variants in the coding sequence of 315 genes and uses conventional Fluorescent in Situ Hybridization ("FISH" methods to identify large deletions, amplifications and translocations in 9 different chromosomal loci.
NEO: 4.13 (+0.04)

NeoGenomics Appoints Robert J. Shovlin as Chief Operating Officer
PR Newswire - Mon Sep 29, 4:00PM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today the appointment of Robert Shovlin as Chief Operating Officer. This appointment will be effective as of Mr. Shovlin's expected start date of October 13, 2014.
NEO: 4.13 (+0.04)

NeoGenomics Schedules its Q3 2014 Earnings Release for October 30, 2014
PR Newswire - Wed Sep 24, 2:28PM CDT
NeoGenomics, Inc. (NASDAQ: NEO)announced today that it plans to release its third quarter 2014 financial results on Thursday October 30, 2014.
NEO: 4.13 (+0.04)

3 Under-$10 Stocks Triggering Breakout Trades
at The Street - Wed Sep 10, 6:00AM CDT
Keep these stocks under $10 on your trading radar.
NEO: 4.13 (+0.04), DPRX: 11.36 (-0.08), GCAP: 8.50 (unch)

5 Under-$10 Stocks Making Big Moves Higher
at The Street - Fri Sep 05, 7:18AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
IRMD: 9.95 (+0.11), MY: 2.05 (-0.09), NEO: 4.13 (+0.04), LINC: 2.65 (+0.03), ARO: 2.26 (-0.05)

5 Breakout Stocks Under $10 Set to Soar
at The Street - Thu Aug 28, 1:39PM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
CAMT: 3.05 (-0.05), AGRX: 5.82 (-0.08), NEO: 4.13 (+0.04), CYTR: 2.16 (+0.01), ATRS: 2.37 (+0.04), TA: 10.52 (+0.02)

NeoGenomics Announces Closing of Recent Equity Offering and Exercise in Full of Underwriters' Over-Allotment Option
PR Newswire - Fri Aug 22, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO) (the "Company" , a leading provider of cancer-focused genetic testing services, today announced that it has closed on the public offering of an additional 1.05 million shares of common stock at an offering price of $4.60 per share as a result of the exercise in full of the underwriters' over-allotment option. The total gross proceeds of the offering, including the exercise in full of the over-allotment option were approximately $37.0 million from the sale of a total of 8.05 million common shares. The net proceeds to the Company, after deducting the underwriters' discount and other estimated expenses will be approximately $34.6 million. The Company plans to use the net proceeds for working capital, capital expenditures and for general corporate purposes including potential acquisitions and the repayment of debt.
NEO: 4.13 (+0.04)

NeoGenomics Announces Pricing of $32.2 Million Public Offering
PR Newswire - Fri Aug 15, 8:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO) (the "Company" , a leading provider of cancer-focused genetic testing services, today announced that it has priced an underwritten public offering of 7.0 million shares of common stock at a price to the public of $4.60 per share. The transaction is expected to close on August 20, 2014 and will result in gross proceeds to NeoGenomics of $32.2 million. The net proceeds to the Company, after deducting the underwriters' discounts and other estimated offering expenses, will be approximately $30.0 million. The Company plans to use the net proceeds for working capital, capital expenditures and for general corporate purposes, including potential acquisitions and the repayment of debt. NeoGenomics has granted the underwriters a 30-day option to purchase up to an additional 1.05 million shares of common stock to cover over-allotments, if any.
NEO: 4.13 (+0.04)

NeoGenomics Announces Public Offering of Common Stock
PR Newswire - Thu Aug 14, 3:01PM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by NeoGenomics.
NEO: 4.13 (+0.04)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 140

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 203

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 71

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 95

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 126

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 78

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 116

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 172

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading

Top 5 Most Recently Viewed Articles

Bitcoin Faces Criticism While BlackRock Sees Financial Success

Updated Category News Views 167

Bitcoin Under Scrutiny In recent discussions, Peter Schiff has taken to social media to share his critical views on Bitcoin, branding it as a "fake asset." His assertion comes after Bitcoin's price retracement from its historic highs, indicating a significant downturn. Currently, Bitcoin is trading at around $81,000 after once peaking at $110,000. Schiff argues that the...

Continue Reading
Valneva Secures $32.8 Million Contract for IXIARO Vaccine Supply

Updated Category News Views 213

Valneva Expands IXIARO Vaccine Supply with New Contract Valneva SE, a leading specialized vaccine company, has officially announced a significant step forward in its partnership with the U.S. Department of Defense (DoD) by signing a new contract valued at a minimum of $32.8 million for the IXIARO vaccine. This substantial agreement marks another chapter in Valneva's...

Continue Reading
EFGH and Minerva Forge Strategic Partnership for Data Centres

Updated Category News Views 118

EFGH and Minerva Unite to Enhance Ghana's Digital Landscape In a landmark agreement, Embed Financial Group Holdings (EFGH) has joined forces with Minerva Data Limited, a prominent player in digital infrastructure, to create advanced data centres and strengthen the technology ecosystem in Ghana. This collaboration marks a significant step in addressing the growing demand...

Continue Reading
Landsea Homes Achieves Remarkable Growth in Q3 Results

Updated Category News Views 50

Strong Financial Performance in Q3 Landsea Homes Corporation (NASDAQ: LSEA) reported impressive financial results for the third quarter, demonstrating robust performance in the residential homebuilding sector. For the quarter, Landsea Homes achieved a net income of $11.1 million, translating to $0.30 per share. This marks a 29% increase in net income compared to the...

Continue Reading
Urban Logistics REIT: Key Disclosure Insights for Investors

Updated Category News Views 219

Understanding the Disclosure from Urban Logistics REIT In the realm of public trading, disclosures play a pivotal role in keeping investors informed about changes in significant stakes within companies. Recently, Urban Logistics REIT Plc, underlining its commitment to transparency, provided valuable insights through its disclosure concerning investor positions, managed by...

Continue Reading